Dr. Lin has published more than 200 peer-reviewed articles, abstracts, and book chapters on various topics related to cancer immunotherapy, cell therapy, and regenerative medicine. She has been the principal investigator or co-investigator of several clinical trials of chimeric antigen receptor (CAR) T cell therapy, bispecific antibodies, and other novel agents for hematologic malignancies, especially multiple myeloma and lymphoma. She has also contributed to the development and validation of biomarkers, quality of life measures, and predictive models for patients undergoing cell therapy and stem cell transplantation. She has collaborated with national and international researchers, industry partners, and patient advocacy groups to advance the field of cancer immunotherapy and cell therapy.